Exagen (XGN) CEO John Aballi awarded new RSUs and options

Rhea-AI Filing Summary

ABALLI JOHN reported acquisition or exercise transactions in this Form 4 filing.

EXAGEN INC. President and CEO John Aballi reported new equity compensation awards. He received stock options for 100,000 shares at $3.1600 per share, expiring on March 11, 2036, and a grant of 150,000 shares of common stock at no cost.

The 150,000-share award consists of restricted stock units that vest 25% on each of the first four anniversaries of February 21, 2026, with potential full vesting upon certain change-in-control terminations. The options vest 25% on February 21, 2027, then 1/48 of the total each month, with similar change-in-control protection.

After these awards, Aballi directly holds 839,834 shares of common stock and 175,000 stock options, and there are an additional 40,401 shares held indirectly by his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABALLI JOHN

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CA 92081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		150,000(1)	A	$0	839,834	D
Common Stock								40,401	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(right to buy)	$3.16	03/12/2026		A		100,000		(2)	03/11/2036	Common Stock	100,000	$3.16	175,000	D

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units under the issuer's 2019 Incentive Award Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock unit will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of February 21, 2026, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control.

2. The option is exercisable as it vests. 25% of the shares subject to the option vest on February 21, 2027, and 1/48th of the total number of shares subject to the option vest at the end of each calendar month thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. In addition, the stock option may become fully vested upon a qualifying termination of employment in connection with a change in control.

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did EXAGEN INC. (XGN) CEO John Aballi receive?

John Aballi received stock options for 100,000 shares at $3.1600 and 150,000 restricted stock units. These compensation awards increase his long-term equity stake and align his interests with EXAGEN INC. shareholders through multi-year vesting schedules.

How do John Aballi’s new EXAGEN (XGN) restricted stock units vest?

The 150,000 restricted stock units vest 25% on each of the first, second, third, and fourth anniversaries of February 21, 2026. Vesting requires Aballi’s continued service, with potential full vesting upon a qualifying termination in connection with a change in control.

What are the terms of John Aballi’s new EXAGEN (XGN) stock options?

Aballi’s stock options cover 100,000 shares at an exercise price of $3.1600 and expire March 11, 2036. Twenty-five percent vest on February 21, 2027, with the remainder vesting in equal monthly installments over the following three years.

How many EXAGEN (XGN) shares does CEO John Aballi hold after these grants?

Following these awards, Aballi directly holds 839,834 shares of EXAGEN common stock and 175,000 stock options. In addition, 40,401 shares are reported as held indirectly by his spouse, reflecting total reported equity exposure from this filing.

Are John Aballi’s new EXAGEN (XGN) equity awards tied to a change in control?

Yes. Both the restricted stock units and the stock options may become fully vested upon a qualifying termination of Aballi’s employment in connection with a change in control, providing protection if control of EXAGEN INC. shifts.